A team at the University of Pittsburgh School of Medicine in the United States said they were able to move quickly in developing a potential COVID-19 vaccine. (Reuters)
By Reuters
April 2, 2020
Potential COVID-19 Vaccine Shows Promise in Mouse Study
LONDON — Initial tests in mice of a potential COVID-19 vaccine delivered via a fingertip-sized patch have shown it can induce an immune response against the new coronavirus at levels that might prevent infection, U.S. scientists said on Thursday.
Researchers around the world are working to develop potential treatments or vaccines against the respiratory disease that has killed nearly 47,000 people and infected almost a million in just a few months.
A team at the University of Pittsburgh School of Medicine in the United States said they were able to move quickly in developing a potential COVID-19 vaccine after working on other coronaviruses that cause Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).
“These two viruses, which are closely related to SARS-CoV-2 (the new coronavirus causing the COVID-19 pandemic), teach us that a particular protein, called a spike protein, is important for inducing immunity against the virus,” said Andrea Gambotto, an associate professor at Pittsburgh.
“We knew exactly where to fight this new virus.”
When tested in mice, the prototype vaccine – which the researchers have called PittCoVacc – generated what they described as “a surge of antibodies” against the new coronavirus within two weeks.
The Pittsburgh researchers cautioned that because the animals have not been tracked for very long as yet, it is too early to say whether and for how long the immune response against COVID-19 lasts.
But they said that in comparable tests in mice with their MERS experimental vaccine, a sufficient level of antibodies was produced to neutralize the virus for at least a year.
So far, the antibody levels of the SARS-CoV-2 vaccinated animals seem to be following the same trend, they said in peer-reviewed study in the journal EBioMedicine.
The team said they hope to start testing the vaccine candidate on people in clinical trials in the next few months.
The potential vaccine uses a needle patch design, called a microneedle array, to increase its potential potency.
This array is a fingertip-sized patch of 400 tiny needles made out of sugar and the spike protein, Gambotto explained. It is designed to deliver the spike protein pieces into the skin, where the immune reaction is strongest.
—
Related:
Social Distancing Works. The Earlier the Better, California & Washington Data Show.
Over 10 million Americans Apply for Unemployment Due to Coronavirus (LATEST UPDATE)
U.N. Chief Calls Pandemic Biggest Global Challenge Since World War II
2020 Ethiopia Election Canceled Due to COVID-19
Getting Through COVID 19: ECMAA Shares Timely Resources With Ethiopian Community
U.S. Approves Malaria Drug to Treat Coronavirus Patients
The Curious Case of Ethiopian Traditional Medicine Covid19 Treatment & Need for Caution
2020 Olympics Rescheduled for July 2021
Haile Gebrselassie Donates to Ethiopia Covid-19 Fund
Maryland Issues COVID-19 Fact Sheet in Amharic for Ethiopian Community
Art in the Time of Coronavirus: Guide to Virtual Exhibitions from Ethiopia to U.S.
We Need Seismic Change, Right Now: by Marcus Samuelsson
City Sleeps: A Look At The Empty NYC Streets Amid The Virus – In Pictures
Ethiopia enforces 14-day quarantine for all travelers
Diaspora-based Tech Professionals Launch Ethiopia COVID-19 Response Task Force
Amid COVID-19 Pandemic Hopeful & Inspiring Stories Shared by Obama
Pleas to Diaspora to Assist Coronavirus First Responders in Ethiopia
Coronavirus Sparks an Epidemic of People Helping People in Seattle
Join the conversation on Twitter and Facebook.
